Vatalanib succinate
CAS: 212142-18-2
Ref. 3D-MIA14218
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar | ||
| 250mg | A consultar |
Información del producto
- 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
- Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)
- Cgp 79787D
- N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine butanedioate
- N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine butanedioate (1:1)
- Ptk 787
- Ptk 787/Zk 222584
- Ptk 787Zk22258
- Zk 222584
Vatalanib succinate is a small molecule drug that inhibits the activity of the vascular endothelial growth factor receptor (VEGFR). Vatalanib succinate binds to the VEGFR and prevents it from binding to its ligands, such as stem cell factor. It has been shown to inhibit metastatic colorectal cancer in animal models. Vatalanib succinate also has biological effects on other cancer cells, including HL-60 cells and mcf-7 cells. The combination of vatalanib succinate with other compounds, such as colony-stimulating factors or toll-like receptor antagonists, may have synergistic effects.
Propiedades químicas
Consulta técnica sobre: 3D-MIA14218 Vatalanib succinate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
